TCIM
REGN icon

TIAA CREF Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

TIAA CREF Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$104M Buy
253,874
+131,687
+108% +$54.2M 0.07% 246
2018
Q4 		$45.6M Sell
122,187
-79,273
-39% -$29M 0.04% 403
2018
Q3 		$81.4M Buy
201,460
+32,436
+19% +$12.3M 0.05% 322
2018
Q2 		$58.3M Sell
169,024
-41,609
-20% -$13M 0.04% 406
2018
Q1 		$72.5M Sell
210,633
-17,268
-8% -$6.01M 0.05% 343
2017
Q4 		$85.7M Sell
227,901
-157,674
-41% -$63.9M 0.06% 321
2017
Q3 		$172M Sell
385,575
-99,761
-21% -$47.5M 0.12% 181
2017
Q2 		$238M Buy
485,336
+239,937
+98% +$105M 0.17% 137
2017
Q1 		$95.1M Sell
245,399
-8,526
-3% -$3.16M 0.07% 300
2016
Q4 		$93.2M Sell
253,925
-28,443
-10% -$10.8M 0.07% 289
2016
Q3 		$114K Buy
282,368
+11,694
+4% +$4.69M 0.07% 270
2016
Q2 		$94.5M Sell
270,674
-28,922
-10% -$11.1M 0.07% 281
2016
Q1 		$108M Sell
299,596
-8,800
-3% -$3.63M 0.08% 247
2015
Q4 		$167M Sell
308,396
-6,468
-2% -$3.5M 0.13% 172
2015
Q3 		$146M Buy
314,864
+16,794
+6% +$9.02M 0.11% 190
2015
Q2 		$152M Sell
298,070
-69,808
-19% -$34.1M 0.11% 214
2015
Q1 		$166M Sell
367,878
-12,164
-3% -$5.16M 0.12% 207
2014
Q4 		$156M Buy
380,042
+96,739
+34% +$38M 0.11% 211
2014
Q3 		$102M Sell
283,303
-15,564
-5% -$5.22M 0.07% 293
2014
Q2 		$84.4M Sell
298,867
-76,484
-20% -$22.7M 0.06% 352
2014
Q1 		$113M Sell
375,351
-14,701
-4% -$4.53M 0.08% 274
2013
Q4 		$107M Buy
390,052
+98,731
+34% +$28.4M 0.08% 280
2013
Q3 		$91.1M Sell
291,321
-8,811
-3% -$2.32M 0.07% 293
2013
Q2 		$67.5M Buy
+300,132
New +$69.9M 0.06% 369

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TIAA CREF Investment Management's REGN Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 108% in Q1 2019, buying an estimated $54.2M and bringing the position to 253,874 shares worth $104M. The position accounts for 0.07% of the portfolio, ranked #246.

TIAA CREF Investment Management first reported a position in REGN in Q2 2013 and has held it in 24 quarters since. The position peaked at $238M in Q2 2017. 718 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

  • TIAA CREF Investment Management held 253,874 shares of Regeneron Pharmaceuticals worth $104M as of Q1 2019.
  • TIAA CREF Investment Management bought 131,687 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $54.2M.
  • Regeneron Pharmaceuticals made up 0.07% of TIAA CREF Investment Management's portfolio in Q1 2019, its #246 holding.
  • TIAA CREF Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Regeneron Pharmaceuticals position peaked at $238M in Q2 2017.
  • 718 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.